Ubs Oconnor LLC Rigel Pharmaceuticals Inc Transaction History

Ubs Oconnor LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.12 - $1.57 $253,775 - $355,738	-226,585 Reduced 25.19%	672,750 $995,000
Q4 2023 Feb 14, 2024	SELL	$0.72 - $1.56 $181,749 - $393,790	-252,430 Reduced 21.92%	899,335 $1.3 Million
Q3 2023 Nov 14, 2023	BUY	$1.07 - $1.39 $133,750 - $173,750	125,000 Added 12.17%	1,151,765 $1.24 Million
Q2 2023 Aug 14, 2023	BUY	$1.12 - $1.82 $1.15 Million - $1.87 Million	1,026,765 New	1,026,765 $1.32 Billion
Q1 2023 May 15, 2023	BUY	$1.25 - $2.0 $239,215 - $382,744	191,372 Added 33.8%	757,511 $999,000
Q4 2022 Feb 14, 2023	BUY	$0.67 - $11.9 $187,600 - $3.33 Million	280,000 Added 97.85%	566,139 $0
Q3 2022 Nov 14, 2022	SELL	$1.1 - $12.2 $159,566 - $1.77 Million	-145,060 Reduced 33.64%	286,139 $338 Million
Q2 2022 Aug 12, 2022	BUY	$0.67 - $3.19 $121,403 - $578,024	181,199 Added 72.48%	431,199 $487,000
Q1 2022 May 16, 2022	SELL	$2.22 - $3.45 $444,000 - $690,000	-200,000 Reduced 44.44%	250,000 $747,000
Q2 2018 Aug 14, 2018	BUY	$2.83 - $4.11 $1.27 Million - $1.85 Million	450,000 New	450,000 $0

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.96B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

Stay updated on Ubs Oconnor LLC with notifications on news.